市場調查報告書
商品編碼
1123184
發炎性腸道疾病的全球市場預測(2022年~2028年)Global Inflammatory Bowel Disease Market Research and Forecast 2022-2028 |
全球發炎性腸道疾病(IBD)的市場規模,在預測期間內預計以5.6%的大幅度的年複合成長率成長。
IBD治療的強力開發中產品的存在和臨床試驗活動的擴大,是推動市場成長的主要要素之一。
本報告提供全球發炎性腸道疾病市場相關調查分析,市場概要,各市場區隔、地區的市場分析,競爭情形,企業簡介等系統性資訊。
Global Inflammatory Bowel Disease (IBD) Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn's Disease), by Diagnosis Method (Blood And Stool Tests, Endoscopies, Ultrasound, and X-Rays), and by Treatment Approach (Surgery and Anti-Inflammatory Drug Administration) Forecast Period (2022-2028)
The global IBD market is anticipated to grow at a substantial CAGR of 5.6% during the forecast period. Growing clinical trial activities coupled with the presence of strong pipeline products for treating IBD are some of the major factors that are driving the market growth. According to the US National Library of Medicine, as of October 2019, there are a total of 730 clinical trials including drug development, observational studies, and others related to IBD. Additionally, out of these 268 clinical trials were conducted in the US only.
The global IBD market is segmented based on disease type, diagnosis method, and treatment approach. Based on the disease type, the market is sub-segmented into ulcerative colitis and Crohn's disease. Based on the diagnosis method, the market is sub-segmented into blood and stool tests, endoscopies, ultrasound, and X-rays. Based on the treatment approach, the market is further augmented into surgery and anti-inflammatory drug administration. The surgery segment includes surgery for Crohn's and ulcerative diseases. Further, the anti-inflammatory drug administration comprises steroids, immunosuppressants, biological drugs, amino salicylates, and others (antibiotics and symptomatic drugs). Among the disease type, the Crohn's disease segment is anticipated to hold a prominent share in the global IBD market, owing to the rapidly increasing incidence rate, and prescription rate of biologics. According to Crohn's and Colitis Foundation, around 25% of patients with Crohn's disease in the US have been prescribed biologics every year.
Geographically the global IBD market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds a prominent market for IBD owing toa large number of patients in the region coupled with the most advanced healthcare infrastructure. On contrary, the Asia-Pacific regional market for IBD treatment is anticipated to grow at the fastest CAGR over the forecast period. The increasing prevalence of Crohn's and ulcerative colitis along with rapidly rising novel drug approval are expected to drive the market. According to a study published by NCBI, in 2019, the prevalence of Crohn's disease is higher in men compared to women. The highest incidence of IBD was observed in East Asian countries including Japan, Korea, China, and others.
The major companies serving the global IBD market include Abbott Laboratories, Amgen, Inc, AstraZeneca PLC, Baxter International Inc., Bristol-Myers Squibb Company, Cosmo pharmaceuticals, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2022, the Indian Council of Medical Research (ICMR) launched IBD NutriCare Application for IBD patients on the occasion of World Inflammatory Bowel Disease Day. This digital health platform for tele-nutrition provides a potential tool for improving the patient care in IBD.
Research Methodology
The market study of the global IBD market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.
The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
Global Inflammatory Bowel Disease (IBD)Market Research and Analysis by Disease Type.
Global Inflammatory Bowel Disease (IBD)Market Research and Analysis by Diagnosis Method.
Global Inflammatory Bowel Disease (IBD)Market Research and Analysis by Treatment Approach.
The Report Covers
Comprehensive research methodology of the global inflammatory bowel disease (IBD) market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global inflammatory bowel disease (IBD) market.
Insights about market determinants that are stimulating the global customer inflammatory bowel disease (IBD) market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.